Predict your next investment

Venture Capital
omegafunds.com

See what CB Insights has to offer

Investments

93

Portfolio Exits

37

Funds

4

About Omega Funds

Omega Funds is an international investment firm that creates and invests in life sciences companies that target the world’s most urgent medical needs.

Omega Funds Headquarter Location

888 Boylston Street Suite 1111

Boston, Massachusetts, 02199,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Omega Funds

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Omega Funds in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing Omega Funds

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Omega Funds in 4 CB Insights research briefs, most recently on Feb 16, 2021.

Latest Omega Funds News

Upstream Bio Launches With $200M Series A

Jun 3, 2022

The funding will allow Upstream to advance the company's lead program UPB-101, a clinical-stage monoclonal antibody targeting the TSLP receptor, and build a pipeline of assets to address immune-mediated diseases. The Series A round was led jointly by OrbiMed and Maruho Co., Ltd. with participation from Access Biotechnology, Decheng Capital, HBM Healthcare Investments, TCG X, Omega Funds, Samsara BioCapital, and Altshuler Shaham Provident Funds Ltd. At Upstream Bio we strive to reach the source of inflammation and conquer it. Their lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases. Upstream Bio is leveraging diverse roots and the team's substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

Omega Funds Investments

93 Investments

Omega Funds has made 93 investments. Their latest investment was in Upstream Bio as part of their Series A on June 6, 2022.

CBI Logo

Omega Funds Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/2/2022

Series A

Upstream Bio

$200M

Yes

2

4/13/2022

Series A

CDR-Life

$76M

Yes

5

3/22/2022

Series A

Aerium Therapeutics

No

3

2/7/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/17/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/2/2022

4/13/2022

3/22/2022

2/7/2022

11/17/2021

Round

Series A

Series A

Series A

Series B

Series A

Company

Upstream Bio

CDR-Life

Aerium Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$200M

$76M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

5

3

10

10

Omega Funds Portfolio Exits

37 Portfolio Exits

Omega Funds has 37 portfolio exits. Their latest portfolio exit was CinCor Pharma on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

$99M

Public

4

12/21/2021

Acquired

$99M

10

12/20/2021

Acquired

$99M

9

12/20/2021

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

8/6/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

12/21/2021

12/20/2021

12/20/2021

8/6/2021

Exit

IPO

Acquired

Acquired

Acq - Pending

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

4

10

9

10

10

Omega Funds Fund History

4 Fund Histories

Omega Funds has 4 funds, including Omega Fund VII.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/17/2021

Omega Fund VII

$650M

1

12/11/2019

Omega Fund VI

Subscribe to see more

Subscribe to see more

$99M

10

5/8/2015

Omega Fund V LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2013

Omega Fund IV LP

Subscribe to see more

Subscribe to see more

10

Closing Date

12/17/2021

12/11/2019

5/8/2015

12/31/2013

Fund

Omega Fund VII

Omega Fund VI

Omega Fund V LP

Omega Fund IV LP

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$650M

$99M

$99M

Sources

1

10

10

10

Omega Funds Team

2 Team Members

Omega Funds has 2 team members, including current Founder, Managing Partner, Otello Stampacchia.

Name

Work History

Title

Status

Otello Stampacchia

AlpInvest Partners, and Goldman Sachs

Founder, Managing Partner

Current

Anne-Mari Paster

MPM Capital, and Third Rock Ventures

Chief Financial Officer

Current

Name

Otello Stampacchia

Anne-Mari Paster

Work History

AlpInvest Partners, and Goldman Sachs

MPM Capital, and Third Rock Ventures

Title

Founder, Managing Partner

Chief Financial Officer

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.